MK-677 (ibutamoren)

At a glance

Overview

Although often sold alongside peptides, MK-677 is a small molecule rather than an amino-acid chain. Oral activity helped make it attractive for long-term GH-secretagogue research. In older-adult trials it increased GH, IGF-1, and fat-free mass, but those changes did not establish improved strength or everyday function. A large Alzheimer disease trial found no clinical slowing despite clear IGF-1 increases. Development under the name LUM-201 continues in selected children with GH deficiency, including a registered phase 3 study. These distinct programs should not be merged into a general claim that ibutamoren treats aging or safely builds useful muscle.

Supporting sources [1] [2] [3] [4]

How it works

Ibutamoren activates the ghrelin receptor, stimulating hypothalamic–pituitary GH secretion and downstream IGF-1. Ghrelin signaling also influences appetite, and raising GH can reduce insulin sensitivity. The compound is therefore pharmacologically broader than an isolated muscle-building signal. Increased lean mass can include changes in body water and does not automatically represent stronger contractile tissue or improved physical performance.

Supporting sources [1] [2] [3] [4]

Lean mass is not the same as physical benefit

In a randomized study of 65 older adults, ibutamoren increased GH and fat-free mass without establishing a corresponding improvement in strength or function. Appetite, body weight, glucose, and insulin sensitivity also changed. The trial supports endocrine activity but not a claim of proven prevention of disability or age-related frailty.

Supporting sources [1]

Negative outcomes and ongoing development

A 563-participant Alzheimer trial found no slowing of clinical progression despite increased IGF-1. Separately, LUM-201 is being studied in children with GH deficiency in a registered phase 3 trial. An active study is evidence of development, not evidence that its endpoint has been met or that regulatory approval has been granted.

Supporting sources [2] [4]

Metabolic and cardiovascular concerns

FDA identifies potential congestive heart failure risk, citing a hip-fracture recovery trial stopped early for a safety signal. Older-adult research also found reduced insulin sensitivity and increased fasting glucose. These findings are particularly relevant when marketing emphasizes muscle or recovery while omitting fluid balance, diabetes risk, and vulnerable patient groups.

Supporting sources [1] [3]

What is its current status?

No FDA-approved ibutamoren medicine or anti-aging indication is established by these sources. FDA’s compounding review identifies significant safety concerns. LUM-201 trial participation, an internet research-product label, and a prescription from a clinic are different contexts and should not be described as equivalent evidence of product approval.

Supporting sources [3] [4]

Is ibutamoren actually a peptide?

No. Ibutamoren is a small-molecule ghrelin-receptor agonist, despite frequently appearing in peptide catalogs. It stimulates the growth-hormone pathway but is not growth hormone itself. Its chemistry and ability to raise IGF-1 do not establish an approved treatment for aging, bodybuilding or athletic recovery.

Supporting sources [1] [2]